Effect of plasmapheresis on ligand binding capacity and expression of erythrocyte complement receptor type 1 (CR1) of patients with systemic lupus erythematosus (SLE)

I. Csípő, E. Kiss, P. Soltész, P. Antal-Szalmás, G. Szegedi, J. H M Cohen, R. P. Taylor, Maria Kávai

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The functional activity and the expression of CR1 on the erythrocytes (E) of patients with SLE were, respectively, determined by measuring the binding to E of either complement-opsonized bovine serum albumin (BSA)-anti- BSA immune complexes (ICC) or specific anti-ECR1 MoAbs. We found that both the functional activity and levels of ECR1 in SLE patients homozygous for ECR1 high density allele were significantly lowered compared with healthy controls having the same allele. Soon after plasmapheresis there was a significant increase in E ICC binding activity, and this increased functional activity was stable. Moreover, plasmapheresis reduced the level of immune complexes demonstrable in the circulation of the patients. The expression of ECR1 determined with several different anti-CR1 MoAbs was also elevated as a consequence of plasmapheresis. This elevation was observed for both MoAb 1B4, which competes for the ICC binding site of ECR1, and for MoAb HB8592, which does not, but the time course for the increase in binding of the two MoAbs was different, in that the epitope recognized by MoAb 1B4 increased more rapidly. The present results, considered in the context of previous findings, suggest that more than one mechanism may be operative with respect to the effects of the plasmapheresis in increasing ECR1 levels defined by different epitopes on the molecule.

Original languageEnglish
Pages (from-to)458-464
Number of pages7
JournalClinical and Experimental Immunology
Volume118
Issue number3
DOIs
Publication statusPublished - 1999

Fingerprint

Complement Receptors
Plasmapheresis
Systemic Lupus Erythematosus
Erythrocytes
Ligands
Bovine Serum Albumin
Antigen-Antibody Complex
Epitopes
Alleles
Binding Sites

Keywords

  • Clearance
  • Erythrocyte CR1
  • Immune complex
  • Plasmapheresis
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Immunology

Cite this

@article{62489e80946147f38e88a12ba4fa0614,
title = "Effect of plasmapheresis on ligand binding capacity and expression of erythrocyte complement receptor type 1 (CR1) of patients with systemic lupus erythematosus (SLE)",
abstract = "The functional activity and the expression of CR1 on the erythrocytes (E) of patients with SLE were, respectively, determined by measuring the binding to E of either complement-opsonized bovine serum albumin (BSA)-anti- BSA immune complexes (ICC) or specific anti-ECR1 MoAbs. We found that both the functional activity and levels of ECR1 in SLE patients homozygous for ECR1 high density allele were significantly lowered compared with healthy controls having the same allele. Soon after plasmapheresis there was a significant increase in E ICC binding activity, and this increased functional activity was stable. Moreover, plasmapheresis reduced the level of immune complexes demonstrable in the circulation of the patients. The expression of ECR1 determined with several different anti-CR1 MoAbs was also elevated as a consequence of plasmapheresis. This elevation was observed for both MoAb 1B4, which competes for the ICC binding site of ECR1, and for MoAb HB8592, which does not, but the time course for the increase in binding of the two MoAbs was different, in that the epitope recognized by MoAb 1B4 increased more rapidly. The present results, considered in the context of previous findings, suggest that more than one mechanism may be operative with respect to the effects of the plasmapheresis in increasing ECR1 levels defined by different epitopes on the molecule.",
keywords = "Clearance, Erythrocyte CR1, Immune complex, Plasmapheresis, Systemic lupus erythematosus",
author = "I. Cs{\'i}pő and E. Kiss and P. Solt{\'e}sz and P. Antal-Szalm{\'a}s and G. Szegedi and Cohen, {J. H M} and Taylor, {R. P.} and Maria K{\'a}vai",
year = "1999",
doi = "10.1046/j.1365-2249.1999.01073.x",
language = "English",
volume = "118",
pages = "458--464",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Effect of plasmapheresis on ligand binding capacity and expression of erythrocyte complement receptor type 1 (CR1) of patients with systemic lupus erythematosus (SLE)

AU - Csípő, I.

AU - Kiss, E.

AU - Soltész, P.

AU - Antal-Szalmás, P.

AU - Szegedi, G.

AU - Cohen, J. H M

AU - Taylor, R. P.

AU - Kávai, Maria

PY - 1999

Y1 - 1999

N2 - The functional activity and the expression of CR1 on the erythrocytes (E) of patients with SLE were, respectively, determined by measuring the binding to E of either complement-opsonized bovine serum albumin (BSA)-anti- BSA immune complexes (ICC) or specific anti-ECR1 MoAbs. We found that both the functional activity and levels of ECR1 in SLE patients homozygous for ECR1 high density allele were significantly lowered compared with healthy controls having the same allele. Soon after plasmapheresis there was a significant increase in E ICC binding activity, and this increased functional activity was stable. Moreover, plasmapheresis reduced the level of immune complexes demonstrable in the circulation of the patients. The expression of ECR1 determined with several different anti-CR1 MoAbs was also elevated as a consequence of plasmapheresis. This elevation was observed for both MoAb 1B4, which competes for the ICC binding site of ECR1, and for MoAb HB8592, which does not, but the time course for the increase in binding of the two MoAbs was different, in that the epitope recognized by MoAb 1B4 increased more rapidly. The present results, considered in the context of previous findings, suggest that more than one mechanism may be operative with respect to the effects of the plasmapheresis in increasing ECR1 levels defined by different epitopes on the molecule.

AB - The functional activity and the expression of CR1 on the erythrocytes (E) of patients with SLE were, respectively, determined by measuring the binding to E of either complement-opsonized bovine serum albumin (BSA)-anti- BSA immune complexes (ICC) or specific anti-ECR1 MoAbs. We found that both the functional activity and levels of ECR1 in SLE patients homozygous for ECR1 high density allele were significantly lowered compared with healthy controls having the same allele. Soon after plasmapheresis there was a significant increase in E ICC binding activity, and this increased functional activity was stable. Moreover, plasmapheresis reduced the level of immune complexes demonstrable in the circulation of the patients. The expression of ECR1 determined with several different anti-CR1 MoAbs was also elevated as a consequence of plasmapheresis. This elevation was observed for both MoAb 1B4, which competes for the ICC binding site of ECR1, and for MoAb HB8592, which does not, but the time course for the increase in binding of the two MoAbs was different, in that the epitope recognized by MoAb 1B4 increased more rapidly. The present results, considered in the context of previous findings, suggest that more than one mechanism may be operative with respect to the effects of the plasmapheresis in increasing ECR1 levels defined by different epitopes on the molecule.

KW - Clearance

KW - Erythrocyte CR1

KW - Immune complex

KW - Plasmapheresis

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=0032720738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032720738&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2249.1999.01073.x

DO - 10.1046/j.1365-2249.1999.01073.x

M3 - Article

C2 - 10594568

AN - SCOPUS:0032720738

VL - 118

SP - 458

EP - 464

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 3

ER -